Choose HEMLIBRA for your adult and pediatric hemophilia A patients with or without FVIII inhibitors

Learn more about the reduction in treated bleeds

See the zero-bleed results

Find the appropriate dosing option for your patients

 

View the safety profile

ABR=annualized bleed rate; aPCC=activated prothrombin complex concentrate; BPA=bypassing agent; Cl=confidence interval; FVlll=factor VIII; IQR=interquartile range; ISTH=International Society on Thrombosis and Haemostasis; QW=once a week; Q2W=once every 2 weeks; Q4W=once every 4 weeks; TMA=thrombotic microangiopathy.
*Treated bleeds were defined based on an adaptation of standard criteria defined by the ISTH. 12
ABR was calculated with a negative binomial regression model, accounting for the different follow-up times.
Randomized, multicenter, open-label, clinical trial in 109 adult and adolescent males (aged ≥12 years and ≥40 kg) with hemophilia A with FVIII inhibitors who previously received either episodic (on-demand) or prophylactic treatment with BPAs. Patients received HEMLIBRA prophylaxis 3 mg/kg once weekly for the first 4 weeks followed by 1.5 mg/kg once weekly thereafter, or no prophylaxis. Median ABR in HAVEN 1 was 0 (IQR: 0; 3.7) with HEMLIBRA prophylaxis vs 18.8 (IQR: 13.0; 35.1) with no prophylaxis.
§Single-arm, multicenter, open-label, clinical trial in pediatric males (age <12 years, or 12–17 years who weigh <40 kg) with hemophilia A with FVIII inhibitors. Patients received HEMLIBRA prophylaxis at 3 mg/kg once weekly for the first 4 weeks followed by 1.5 mg/kg QW thereafter.